Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000513426 | SCV000341051 | uncertain significance | not provided | 2017-09-18 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000513426 | SCV000609023 | likely benign | not provided | 2021-07-01 | criteria provided, single submitter | clinical testing | |
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000625221 | SCV000744174 | likely benign | Cholestanol storage disease | 2017-06-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000625221 | SCV001051714 | benign | Cholestanol storage disease | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000513426 | SCV001783758 | likely benign | not provided | 2021-03-26 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002392807 | SCV002699745 | likely benign | Cardiovascular phenotype | 2022-06-22 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Natera, |
RCV000625221 | SCV001462726 | likely benign | Cholestanol storage disease | 2019-12-23 | no assertion criteria provided | clinical testing | |
Clinical Genetics, |
RCV001706418 | SCV001921025 | benign | not specified | no assertion criteria provided | clinical testing |